

Incastuximab tesirine-lpy

PATIENT ENROLLMENT FORM

SUBMIT COMPLETED ENROLLMENT FORM

Fax: 1-855-915-3005 or Email: support@ADVANCINGPatientSupport.com

Enrollment initiates a benefits investigation, providing a summary of the patient's insurance coverage and out-of-pocket costs. Personalized assistance and support for patients is available for the services below. Be sure to check the boxes on page 1 based on the support needed for your patient.

Prior Authorization/Precertification helps determine if a prior authorization or precertification is needed for your patient and can provide support throughout the process

Appeals/Claims Support provides guidance on coding and billing, the appeals process, and can help navigate any questions that may arise

Copay Program enrolls your eligible commercially insured patients^a

Patient Assistance Program (PAP) offers uninsured/underinsured patients ZYNLONTA (loncastuximab tesirine-lpyl) for free if they meet certain criteria

Important Note: Let your patient know that once they are enrolled, they will receive a welcome call from **ADVANCING Patient Support**. Have them save **1-855-690-0340** in their contacts so they recognize the number when called.

It's important to complete this form in its entirety to prevent processing delays. Please contact **ADVANCING Patient Support** at **1-855-690-0340**, Monday-Friday (8 AM–8 PM ET) for assistance.

SECTIONS

Healthcare Provider SIGN & DATE Section 6 (page 2) Section 7 (page 3) Patient SIGN & DATE Section 6 (page 2) Section 8 (pages 4 & 5)

HOW TO ENROLL YOUR PATIENT

1	Patient Information (page 1): Provide patient information.
2	Healthcare Provider Information (page 1): Provide healthcare provider contact information. Be sure to include NPI and DEA numbers to help facilitate the benefits investigation.
3	Infusion/Administration Site (page 1): Provide Infusion/Administration Site details if different than Healthcare Provider information.
4	Insurance Information (page 1): Provide the patient's insurance information. In addition, you may provide a copy of both sides of the patient's insurance card to help improve accuracy and reduce the frequency of follow-up calls.
5	Clinical Information (page 2): Clinical information is important and often needed for the benefits investigation. Diagnosis and appropriate ICD-10 code are required fields. Providing additional information in this section may help reduce the frequency of follow-up calls.
6	Patient Assistance Program (PAP) (page 2): This section can serve as the prescription for ZYNLONTA for patients enrolled in ADVANCING Patient Support . Please ensure the prescribing healthcare provider and your patient sign this section. Be sure to attach a separate prescription if this section does not comply with your state's prescription law.
7	Healthcare Provider Certific tion (page 3): A healthcare provider's signature is required to attest to the review and certification of the program request.
8	Patient Authorization (pages 4 & 5): Requires patient (or legal representative) signatures for consent for product and

^aFor commercially insured patients only. Eligibility and other restrictions apply. For full Terms and Conditions, visit **ADVANCINGPatientSupport.com** /copay-terms-conditions.

program communications and Patient Certification and HIPAA Authorization.

SUBMIT COMPLETED ENROLLMENT FORM Fax: 1-855-915-3005 or Email: support@ADVANCINGPatientSupport.com For more information, contact your ADVANCING Patient Support case manager at 1-855-690-0340 Monday-Friday (8 AM-8 PM ET)

Zynlonta,

atient Support

PATIENT ENROLLMENT FORM

Page 1 of 5

1 Patient Information	Sex: 🗌 Male 🗌 Female	Date of Birth: / /	
Patient's Name:			
Patient's Address:			
Best Time to Contact: 🗌 AM (8 AM–10 AM ET) 🗌 Day (10 AM–5 PM ET) 🗌 Evening (5 PM–8 PM ET)			
Legal Representative (if applicable	e):		
Phone:	Email:		
ation			
	Provi	der's Title:	
	а .н.		
Offic	ce Contact's Email/Direct Phone:		
	Patient's Name: First Patient's Address: City: Home Phone: Email: Best Time to Contact: □ AM (8 AM- Legal Representative (if applicable Relationship to Patient: Phone: Last DE DE PTAN#:	Patient's Name:	

3 Infusion/Administration Site (if different from above)

Facility/Site Name:			
Office Contact's Name:			
Address:			
		Stata	Zip:
City:		State:	_ Zip:

4 Insurance Information

□ Uninsured □ Commercial □ Medicare □ Medicaid □ Other:	□ Uninsured	🗆 Commercial 🛛 Medi	re 🗌 Medicaid	□ Other:
---	-------------	---------------------	---------------	----------

□ Government Programs (please specify):_

For the best experience, please attach a copy of the patient's insurance card

Primary Medical Ins	urance Payer:	Secondary Medical Insurance Payer:	
Phone:		Phone:	
Group#:		Group#:	
BIN:	PCN:	BIN: PCN:	
	First Last	Policy Holder Name: First Last	
Policy Holder Relation		Policy Holder Relationship to Patient:	

1-855-690-0340 Monday-Friday (8 AM-8 PM ET) | www.ADVANCINGPatientSupport.com



First



Patient's Name:

Date of Birth: ____ / ____ / ____

SUBMIT COMPLETED ENROLLMENT FORM Fax: 1-855-915-3005 or Email: support@ADVANCINGPatientSupport.com For more information, contact your ADVANCING Patient Support case manager at 1-855-690-0340 Monday-Friday (8 AM–8 PM ET)

Last

5 Clinical Information		
Patient's Diagnosis:	ICD-10-CM Code:	Diagnosis Date: / /
Most Recent Therapies for this Diagnosis:		
Prior Therapies for this Diagnosis:		
Drug Allergies:		
Other Medications:		

Patient Assistance Program (PAP) Enrollment (if applicable)				
6 ZYNLONTA® (loncastuximab tesirine-lpyl) Prescription for PAP				
Patient's Name:/ Weight: Date of Birth:// Weight:				
Prescription 1 (Cycle 1 and 2)	Prescription 2 (Cycles 3+)			
ZYNLONTA Start Date: //	ZYNLONTA Start Date: //			
Directions: 0.15 mg/kg intravenous infusion every 3 weeks for 2 cycles	Directions: 0.075 mg/kg intravenous infusion every 3 weeks for subsequent cycles			
Premedicate with dexamethasone 4 mg orally or intravenously twice daily for 3 days beginning the day before ZYNLONTA	Premedicate with dexamethasone 4 mg orally or intravenously twice daily for 3 days beginning the day before ZYNLONTA			
Other Directions:	Other Directions:			
Quantity: 10 mg vial(s) 1 Refill	Quantity: 10 mg vial(s) Refills			
Healthcare Provider's Name:				
Healthcare Provider's Signature: No stamps please.	Date: //			

Patient to Complete

I certify that the information provided on this form is complete and accurate, to the best of my knowledge, and I will promptly call ADC Therapeutics at 1-855-690-0340 with any updates, including any changes to my insurance. I understand that all support provided through the ADVANCING Patient Support Program (the "Program") is complimentary, and there is no purchase requirement associated with the Program. To determine my eligibility to enroll into the Patient Assistance Program, ADC Therapeutics and its representatives/agents ("ADC Therapeutics") will assess my income with the appropriate level of evidence set forth by verification of financial information (including W-2 and tax return documentation). I will not seek (or allow others to seek on my behalf) payment or reimbursement for any free drug or other support provided to me through the Program. I will comply with all Program Terms and Conditions and with any requirements from my insurance provider.

Fair Credit Reporting Act (FCRA) Authorization: I am providing written instructions authorizing the Program and its vendor to obtain my consumer report from a consumer reporting agency to be used solely for the eligibility determination process for programs administered by ADC Therapeutics.

Patient's or Legal Representative's Signature:

Date: ____ / ____ / ___

PATIENT ENROLLMENT FORM

Patient's Name:

Last

Date of Birth: ____ _ / _

SUBMIT COMPLETED ENROLLMENT FORM Fax: 1-855-915-3005 or Email: support@ADVANCINGPatientSupport.com For more information, contact your ADVANCING Patient Support case manager at 1-855-690-0340 Monday-Friday (8 AM-8 PM ET)

7 Healthcare Provider Certification

First

Patient Support

By signing below, I hereby represent, covenant, and certify as follows:

Zynlonta

loncastuximab tesirine-lpy

- (1) The above therapy (or medicine) is medically necessary;
- (2) I have obtained from my patient his or her consent and any required written authorization as required by HIPAA and other federal or state laws to release to ADC Therapeutics America, Inc. and its representatives/agents ("ADC Therapeutics") all patient information needed for processing this application, including, without limitation, my patient's financial and medical information;
- (3) I understand and my patient has authorized that this information may be used by ADC Therapeutics to assess the patient's eligibility for participation in ADVANCING Patient Support Program (the "Program") and for other purposes as outlined in the Patient Authorization below;
- (4) ADC Therapeutics is authorized to contact me about the information provided on this form and as needed to facilitate my patient's enrollment and participation in the Program;
- (5) I have read and understand the Terms and Conditions of the Copay Assistance Program available from ADVANCING Patient Support Program (the "Program") or at www.ADVANCINGPatientSupport.com/copayterms-conditions and I agree to be bound by these Copay Assistance Program Terms and Conditions;
- (6) I have not received, nor will I seek or accept reimbursement from any federal, state, or private payers for any drug provided for my patient through the Program's free-drug support ("Patient Assistance Program" or "PAP");
- (7) If the above-named patient is enrolled in ADC Therapeutics Patient Assistance Program, free ZYNLONTA (loncastuximab tesirine-lpyl) will be provided to this eligible and enrolled patient at no charge of any kind; free ZYNLONTA that is supplied as a result of this enrollment form is for the use of the patient named on this form only and shall not be sold, traded, bartered, transferred, returned for credit, or submitted to any third party (such as Medicare, Medicaid, or other benefit provider) for reimbursement. I understand that ADC Therapeutics may contact the patient directly to complete the enrollment form and, if authorized by the patient, contact the patient directly in the future to verify Program eligibility and updates to insurance coverage as well as to confirm the receipt of free ZYNLONTA through the Program;
- (8) I have not received, nor will I seek or accept payment from my patient or any other payer for any co-insurance or other cost-sharing amount paid for by the Program;
- (9) I understand that if my patient's insurance or financial status changes, the patient may no longer be eligible under this Program. I will promptly notify ADC Therapeutics by calling 1-855-690-0340 if I become aware of any such changes;
- (10) I understand that any ADC Therapeutics products and other support provided by the Program are complimentary and for the benefit of the patient, that I am under no obligation to prescribe any ADC Therapeutics drugs, including because of my patient's participation in the Program, and I have not received and will not receive any benefit from ADC Therapeutics for prescribing an ADC Therapeutics drug;
- (11) I understand that if I receive free ADC Therapeutics product, I will only administer it to the patient identified in this application for whom it was prescribed or return the product to ADC Therapeutics;
- (12) The information contained in this form is complete and accurate to the best of my knowledge; and
- (13) I will promptly notify ADC Therapeutics of any errors by calling 1-855-690-0340, and will make every effort to correct those errors.

Healthcare Provider's Name:		
Healthcare Provider's Signature:		Date: / /
	No stamps please	



Patient's Name: ____

PATIENT ENROLLMENT FORM

Date of Birth: ____ / ____ / ____

SUBMIT COMPLETED ENROLLMENT FORM Fax: 1-855-915-3005 or **Email:** support@ADVANCINGPatientSupport.com For more information, contact your ADVANCING Patient Support case manager at 1-855-690-0340 Monday-Friday (8 AM–8 PM ET)

Last

8 Patient Authorization

Patient Support

First

Consent to Receive Product and Support Communications

Zynlonta Concastuximab tesirine-lpyl

ADC Therapeutics understands protecting your personal and health information is very important. We do not share any personally identifiable or health information you give us with third parties for their own marketing use. I understand from time to time, ADC Therapeutics Privacy Policy may change and for the most recent version of the Privacy Policy, I should visit https://adctherapeutics. com/privacy-policy/. I understand by signing below that the information provided by me, my healthcare professional, pharmacy, or insurance company may be used for marketing purposes by ADC Therapeutics in order to share updates about its products and services, or other opportunities that may be of interest to me via mail, email, or phone. I can opt out of marketing communications at any time by clicking the unsubscribe link in the emails I receive from ADCT or by sending a letter with my opt out request to 430 Mountain Avenue, Suite #404, New Providence, NJ 07974, Attn: ADCT Marketing.

Patient's or Legal Representative's Signature: _____ / ___ / ___ / ___ Date: ____ / ___ / ___ / ___ / ___ / ___

Patient Certification and HIPAA Authorization

I certify that the information I am providing on this form is true and correct. I further certify that I have read and understand the Terms and Conditions of the Copay Assistance Program available from ADVANCING Patient Support Program (the "Program") or at www.ADVANCINGPatientSupport. com/copay-terms-conditions, that I meet the eligibility requirements for, and I agree to be bound by these Copay Assistance Program Terms and Conditions.

I hereby authorize my healthcare providers, my health insurance company, and my pharmacy to disclose my protected health information ("PHI") including, but not limited to, my name, address, telephone number, medical records, health insurance coverage, and financial information to ADC Therapeutics America, Inc. and its representatives/agents ("ADC Therapeutics") so that ADC Therapeutics may use my information: (a) to contact me, or the person legally authorized to sign on my behalf, by phone or mail, regarding this application, my participation in ADVANCING Patient Support Program (the "Program"), the services and information available through the Program, and my use or potential use of ZYNLONTA (loncastuximab tesirine-lpyl), including through messages left for me that disclose that I take or may take ZYNLONTA; (b) to contact my insurance company on my behalf to verify my coverage for ZYNLONTA; (c) to determine my eligibility for enrollment into the Program; (d) to enroll me into the Program, if I am eligible, and provide applicable support through the Program, including information on third-party sources that may be able to assist me; (e) to coordinate my ZYNLONTA treatment with my healthcare professionals and specialty pharmacy, and send me educational materials or other information that may be of interest to me related to my ZYNLONTA treatment, and/or; (f) to conduct other activities as appropriate to administer the Program.

(continued)



PATIENT ENROLLMENT FORM Page 5 of 5

Patient's Name:

Date of Birth: ____ / ____ / ___

SUBMIT COMPLETED ENROLLMENT FORM Fax: 1-855-915-3005 or **Email:** support@ADVANCINGPatientSupport.com For more information, contact your ADVANCING Patient Support case manager at 1-855-690-0340 Monday-Friday (8 AM–8 PM ET)

Last

8 Patient Authorization (continued)

First

loncastuximab tesirine-lpy

If I have designated a Legal Representative on this form, I authorize ADC Therapeutics to use my PHI to contact the person I have designated as my Legal Representative for the purpose of verifying the information I have provided in this form and/or coordinating the provision of benefits that may be available to me under the Program and to disclose my PHI, including information provided in this enrollment form, to my Legal Representative for the purposes described in this paragraph. Once my PHI has been disclosed to ADC Therapeutics, I understand that federal privacy laws, including HIPAA, may no longer protect my PHI.

I understand that neither treatment from my healthcare professional nor coverage for ZYNLONTA through my insurance are conditioned on me signing this certification and authorization. I understand that this certification and authorization is voluntary. However, if I refuse to sign, or revoke my authorization, ADC Therapeutics may not be able to determine my eligibility for the Program and I may not be eligible to participate in the Program. I may revoke this authorization at any time by contacting ADVANCING Patient Support at 1-855-690-0340 or by sending a written request for cancellation to TrialCard, C/O Advancing Patient Support, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560. If I do not revoke this authorization, it will remain valid for 5 years (or at such lesser time as state law may require). I understand that I will be provided with a copy of this authorization by my healthcare provider or health plan (or I am able to request a copy).

Date: ____ / ____ / ____

